
Affiliated with a Castle Connolly Top Hospital
Also known as:
ICD-10 Codes:
Also known as:
ICD-10 Codes:
Also known as:
ICD-10 Codes:
Also known as:
CPT Codes:
Also known as:
CPT Codes:
Also known as:
CPT Codes:
Also known as:
CPT Codes:
Also known as:
CPT Codes:
Also known as:
CPT Codes:
Also known as:
CPT Codes:
All Other Third Party
Blue Shield of California
Care N' Care Insurance Company
Kaiser Permanente
Medicaid
Medicare
Santa Cruz County
State of California
UnitedHealth Group
Unknown
View All Insurances
The prognostic value of diagnosing concurrent multiple myeloma
, 2013
H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells
, 2013
Heart transplantation and cardiac amyloidosis: Approach to screening and novel magement strategies
, 2012
Long-term outcomes in patients with high
, 2011
Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular
, 2010
Infusion of the allogeneic cell line NK-92 in patients with advanced rel cell cancer or melanoma
, 2008
A cost-effectiveness alysis of adjuvant trastuzumab regimens in early HER2
, 2007
tural killer cells: can they be useful as adoptive immunotherapy for cancer?
, 2005
von Willebrand factor
, 2001
The prognostic value of diagnosing concurrent multiple myeloma
, 2013
H-Y antigen-binding B cells develop in male recipients of female hematopoietic cells
, 2013
Prophylactic rituximab after allogeneic transplantation decreases B
, 2012
Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative
, 2012
Heart transplantation and cardiac amyloidosis
, 2012
Adoptive Immunotherapy with Cytokine
, 2011
A phase 1 study of imatinib for corticosteroid-dependent
, 2011
Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH
, 2011
Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative
, 2011
Long-term outcomes in patients with high
, 2011
Complete donor T-cell engraftment 30 days after allogeneic transplantation predicts molecular
, 2010
Phase I/II Trial of GN-BVC,
, 2010
Rituximab in hematopoietic cell transplantation
, 2010
TLI and ATG conditioning with low risk of graft-versus
, 2009
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma
, 2008
A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2
, 2007
Natural killer cells: can they be useful as adoptive immunotherapy for cancer?
, 2005
Association of Foxp3 regulatory gene expression and graft-versus-host disease
, 2004
Poor outcome in steroid refractory GVHD with ATG treatment
, 2002
von Willebrand factor
, 2001